VTGN VISTAGEN THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, VISTAGEN THERAPEUTICS INC reported revenue of $1.48M (up 504.9% from a year earlier), net income of −$13.0M and diluted EPS of −$0.30; over the last four quarters revenue was $2.50M and net income −$67.6M; for the fiscal year ended March 2026 revenue was $1.27M, up 161.1% on the year before.
VTGN annual revenue and earnings
- Fiscal year ended Mar 2026: revenue $1.27M, gross profit n/a, operating income −$72.1M, net income −$69.7M (margin -5491.9%), EPS −$1.83
- Fiscal year ended Mar 2025: revenue $486K, gross profit n/a, operating income −$56.0M, net income −$51.4M (margin -10579.8%), EPS −$1.67
- Fiscal year ended Mar 2024: revenue $1.06M, gross profit n/a, operating income −$33.0M, net income −$29.4M (margin -2759.6%), EPS −$1.52
- Fiscal year ended Mar 2023: revenue −$227K, gross profit n/a, operating income −$59.3M, net income −$59.2M (margin 26100.4%), EPS −$8.51
- Fiscal year ended Mar 2022: revenue $1.11M, gross profit n/a, operating income −$47.8M, net income −$47.8M (margin -4306.8%), EPS n/a
VTGN quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $1.48M (up 504.9% year over year), net income −$13.0M, EPS −$0.30
- Quarter ended Mar 31, 2026 (from the annual report): revenue $464K (up 3193.3% year over year), net income −$16.3M, EPS −$0.37
- Quarter ended Dec 31, 2025: revenue $303K (up 29.5% year over year), net income −$18.9M, EPS −$0.45
- Quarter ended Sep 30, 2025: revenue $258K (up 41.0% year over year), net income −$19.4M, EPS −$0.54
- Quarter ended Jun 30, 2025: revenue $244K (up 190.5% year over year), net income −$15.1M, EPS −$0.47
- Quarter ended Mar 31, 2025 (from the annual report): revenue −$15.0K (down 107.6% year over year), net income −$13.6M, EPS −$0.44
- Quarter ended Dec 31, 2024: revenue $234K (down 43.1% year over year), net income −$14.1M, EPS −$0.46
- Quarter ended Sep 30, 2024: revenue $183K (down 34.2% year over year), net income −$13.0M, EPS −$0.42
- Quarter ended Jun 30, 2024: revenue $84.0K (down 52.5% year over year), net income −$10.7M, EPS −$0.35
- Quarter ended Mar 31, 2024 (from the annual report): revenue $198K (up 12.5% year over year), net income −$9.52M, EPS $0.30
- Quarter ended Dec 31, 2023: revenue $411K (up 128.3% year over year), net income −$6.35M, EPS −$0.22
- Quarter ended Sep 30, 2023: revenue $278K (up 131.1% year over year), net income −$6.59M, EPS −$0.66
- Quarter ended Jun 30, 2023: revenue $177K (down 42.9% year over year), net income −$6.90M, EPS −$0.94
- Quarter ended Mar 31, 2023: revenue $176K (up 351.3% year over year), net income −$12.2M, EPS n/a
- Quarter ended Dec 31, 2022: revenue $180K (down 49.7% year over year), net income −$9.76M, EPS n/a
- Quarter ended Sep 30, 2022: revenue −$893K (down 349.4% year over year), net income −$17.5M, EPS n/a
- Quarter ended Jun 30, 2022: revenue $310K (down 12.4% year over year), net income −$19.8M, EPS n/a
- Quarter ended Mar 31, 2022: revenue $39.0K (down 91.2% year over year), net income −$16.7M, EPS n/a
- Quarter ended Dec 31, 2021: revenue $358K, net income −$10.5M, EPS −$0.05
- Quarter ended Sep 30, 2021: revenue $358K, net income −$12.8M, EPS −$0.07
VTGN cash flow, buybacks and dividends
- Fiscal year ended Mar 2026: operating cash flow −$66.4M, share buybacks n/a
- Fiscal year ended Mar 2025: operating cash flow −$42.1M, share buybacks n/a
- Fiscal year ended Mar 2024: operating cash flow −$25.8M, share buybacks n/a
- Fiscal year ended Mar 2023: operating cash flow −$49.7M, share buybacks n/a
- Fiscal year ended Mar 2022: operating cash flow −$45.3M, share buybacks n/a
VTGN balance sheet
- Jun 30, 2026: cash $17.0M, total assets $35.7M, total liabilities $11.3M, shareholders' equity $24.5M
- Mar 31, 2026: cash $30.8M, total assets $48.6M, total liabilities $13.0M, shareholders' equity $35.5M
- Dec 31, 2025: cash $47.4M, total assets $65.1M, total liabilities $14.1M, shareholders' equity $50.9M
- Sep 30, 2025: cash $62.8M, total assets $80.9M, total liabilities $14.6M, shareholders' equity $66.3M
- Jun 30, 2025: cash $49.0M, total assets $68.9M, total liabilities $12.2M, shareholders' equity $56.8M
- Mar 31, 2025: cash $67.1M, total assets $84.3M, total liabilities $14.0M, shareholders' equity $70.4M
- Dec 31, 2024: cash $74.7M, total assets $92.3M, total liabilities $11.2M, shareholders' equity $81.1M
- Sep 30, 2024: cash $84.2M, total assets $102M, total liabilities $9.52M, shareholders' equity $93.0M
What is VTGN's revenue?
VISTAGEN THERAPEUTICS INC reported $2.50M of revenue over its last four quarters, through June 30, 2026.
Is VTGN profitable?
No. VISTAGEN THERAPEUTICS INC lost $67.6M over the last four quarters.
What is VTGN's EPS?
Diluted earnings per share over the last four quarters were −$1.66; −$0.30 in the latest quarter.